1. Home
  2. RDWR vs VRDN Comparison

RDWR vs VRDN Comparison

Compare RDWR & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Radware Ltd.

RDWR

Radware Ltd.

HOLD

Current Price

$27.90

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo Viridian Therapeutics Inc.

VRDN

Viridian Therapeutics Inc.

HOLD

Current Price

$16.13

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDWR
VRDN
Founded
1996
2006
Country
Israel
United States
Employees
N/A
N/A
Industry
EDP Services
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.4B
IPO Year
2000
2014

Fundamental Metrics

Financial Performance
Metric
RDWR
VRDN
Price
$27.90
$16.13
Analyst Decision
Buy
Strong Buy
Analyst Count
2
14
Target Price
$32.50
$35.46
AVG Volume (30 Days)
199.4K
3.1M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,706,000.00
Revenue This Year
$10.65
$13.73
Revenue Next Year
$8.62
$279.00
P/E Ratio
$59.76
N/A
Revenue Growth
N/A
N/A
52 Week Low
$21.68
$12.83
52 Week High
$30.57
$34.29

Technical Indicators

Market Signals
Indicator
RDWR
VRDN
Relative Strength Index (RSI) 58.23 46.13
Support Level $23.64 $15.68
Resistance Level $29.15 $19.72
Average True Range (ATR) 0.98 0.91
MACD 0.06 0.49
Stochastic Oscillator 60.45 43.84

Price Performance

Historical Comparison
RDWR
VRDN

About RDWR Radware Ltd.

Radware Ltd is a provider of application security and delivery solutions for multi-cloud environments. Its solutions secure the digital experience by providing infrastructure, application, and network protection and availability services to companies globally. Its solutions are deployed by, among others, enterprises, carriers, and cloud service providers. The company offers solutions in two main categories: Products offers a range of cloud-based security-as-a-service subscriptions, on-premises hardware and software products, and product subscriptions (or a combination of these) to customers; and Services offers managed services, professional services, technical support and training and certification to customers and partners.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Share on Social Networks: